Sin­ga­pore grants patent to Su­ven for neuro mol­e­cule

BioSpectrum (Asia) - - Company News -

Su­ven Life Sciences Ltd. has been granted a prod­uct patent from Sin­ga­pore for the New Chem­i­cal En­ti­ties (NCEs) deal­ing with treat­ment of dis­or­ders as­so­ci­ated with Neu­rode­gen­er­a­tive dis­eases. The patent is valid through 2033. The class of se­lec­tive 5-HT4 com­pounds are be­ing de­vel­oped as ther­a­peu­tic agents for the treat­ment of cog­ni­tive im­pair­ment as­so­ci­ated with neu­rode­gen­er­a­tive dis­or­ders like Alzheimer’s dis­ease, At­ten­tion de­fi­cient hy­per­ac­tiv­ity dis­or­der (ADHD), Hunt­ing­ton’s dis­ease, Parkin­son and Schizophre­nia. Su­ven Life Science is fo­cused on dis­cov­er­ing, de­vel­op­ing and com­mer­cial­iz­ing novel phar­ma­ceu­ti­cal prod­ucts, which are first in class for neu­ro­log­i­cal ther­a­pies.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.